Brokerages expect that Trevena Inc (NASDAQ:TRVN) will post ($0.15) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Trevena’s earnings. Trevena posted earnings of ($0.24) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 37.5%. The business is scheduled to issue its next quarterly earnings results on Wednesday, March 6th.

According to Zacks, analysts expect that Trevena will report full year earnings of ($0.55) per share for the current financial year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.62) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Trevena.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.00 million.

Several research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Trevena in a research report on Monday, August 13th. Needham & Company LLC downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. Jefferies Financial Group downgraded shares of Trevena from a “buy” rating to a “hold” rating and reduced their price target for the stock from $10.00 to $1.00 in a research report on Wednesday, October 10th. Finally, JMP Securities raised their price target on shares of Trevena from $4.00 to $15.00 and gave the stock an “outperform” rating in a research report on Friday, October 12th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Trevena currently has a consensus rating of “Buy” and a consensus price target of $5.42.

TRVN stock traded down $0.02 on Friday, hitting $0.63. 574,127 shares of the company were exchanged, compared to its average volume of 929,631. Trevena has a twelve month low of $0.55 and a twelve month high of $3.58. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.30 and a current ratio of 4.30. The firm has a market capitalization of $51.63 million, a price-to-earnings ratio of -0.52 and a beta of 0.54.

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its stake in Trevena by 24.0% during the 2nd quarter. FMR LLC now owns 5,288,100 shares of the biopharmaceutical company’s stock valued at $7,615,000 after buying an additional 1,022,830 shares during the period. Vanguard Group Inc. increased its stake in Trevena by 29.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after buying an additional 592,152 shares during the period. BlackRock Inc. increased its stake in Trevena by 151.4% during the 3rd quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock valued at $3,971,000 after buying an additional 1,128,041 shares during the period. Millennium Management LLC increased its stake in Trevena by 112.3% during the 2nd quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock valued at $1,448,000 after buying an additional 532,129 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Trevena by 67.2% during the 3rd quarter. Renaissance Technologies LLC now owns 872,300 shares of the biopharmaceutical company’s stock valued at $1,849,000 after buying an additional 350,600 shares during the period. 39.10% of the stock is currently owned by hedge funds and other institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

See Also: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.